Pfizer to halt development of closely watched weight-loss drug
The pullback removes one of the larger pipeline bets against Lilly and Novo Nordisk in the obesity market.
www.polskieradio.pl · +14 outlets
Vaxcyte's pneumococcal vaccine matches Pfizer and Merck shots in trial; stock jumps, analysts raise targets
A strong head-to-head readout could position Vaxcyte as a credible challenger in the large pneumococcal vaccine market long dominated by Pfizer and Merck.
Fierce Biotech · +3 outlets
FDA expands Lilly's Jaypirca approval to untreated leukemia patients
The label expansion moves Jaypirca into earlier-line use in chronic lymphocytic leukemia, widening its addressable patient population.
Benzinga · +13 outlets
Rezolute says FDA recommends pre-BLA meeting for rare blood sugar disorder drug after Phase 3 miss
The FDA's willingness to keep engaging signals a possible path forward for Rezolute's congenital hyperinsulinism therapy despite missed trial endpoints.
Benzinga · +4 outlets
AstraZeneca says Tagrisso cuts death risk 47% in early-stage lung cancer
The adjuvant data strengthens Tagrisso's role in earlier treatment of EGFR-mutated lung cancer.
scanx.trade · +6 outlets
Eli Lilly to build $3.5 billion Pennsylvania weight-loss drug plant
The investment expands manufacturing capacity for Lilly's GLP-1 franchise amid sustained demand.
www.polskieradio.pl · +14 outlets
Capricor faces make-or-break FDA panel for Duchenne cell therapy
An advisory committee vote will determine whether the company's cell therapy can reach the U.S. market.
Stocktwits · +2 outlets
Caribou to cut jobs and stop development of two cancer cell therapy programs
The pipeline cull reflects continued pressure on cash-strapped cell therapy developers.
Stock Titan · +2 outlets
Amylyx to present Phase 3 avexitide data at ObesityWeek 2026
Avexitide targets post-bariatric hypoglycemia, a condition with no FDA-approved therapy.
scanx.trade · +5 outlets
Executive order on pharma tariffs brings drug ETFs into focus
Tariff implementation could reshape costs and margins across the pharmaceutical supply chain.
TradingView · +4 outlets
Biotech stocks hit 52-week highs as Vaxcyte jumps 31% on Phase 3 results
A broad rally in biotech names followed strong clinical data and sector momentum.
RTTNews · +1 outlets
Obesity drugs: the next frontier is lasting weight loss
Developers are targeting durability of weight loss as the competitive bar rises.
PharmaVoice · +14 outlets
Prime Medicine stock draws traders on FDA trial wins
Regulatory clearances for gene editing programs have lifted interest in the early-stage biotech.
Timothy Sykes · +1 outlets
Bausch + Lomb advances two eye therapies with $2 billion sales potential
The eye care company is pushing late-stage candidates as it seeks new growth drivers.
scanx.trade · +7 outlets
MFN policy raises the stakes for Japan launch pricing
Most-favored-nation pricing rules are reshaping launch economics for drugmakers in Japan.
Pharmaceutical Executive
Lilly seen dominating the pharma world by 2032 on obesity franchise
Analysts expect GLP-1 leadership to drive long-term industry share gains for Lilly.
MediaPost
Anchen Biotech's AC-203 set for Q4 data readout in epidermolysis bullosa simplex
A positive readout would make AC-203 the first approved treatment for the rare skin condition.
BigGo Finance
Alvotech gets FDA approval to double capacity for a Humira alternative for U.S. supply
Expanded capacity supports U.S. supply of the biosimilar amid Humira competition.
Stock Titan · +1 outlets